Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 251-258, 2007. First published January 2, 2007; 10.1373/clinchem.2006.074989
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 074989.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.074989v1
53/2/251    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sircar, D.
Right arrow Articles by Subbaiah, P. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sircar, D.
Right arrow Articles by Subbaiah, P. V.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2007;53:251-258.)
© 2007 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Isoprostane Measurement in Plasma and Urine by Liquid Chromatography–Mass Spectrometry with One-Step Sample Preparation

Debajit Sircar and Papasani V. Subbaiaha

1 Departments of Medicine and Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL.

aAddress correspondence to this author at: Department of Medicine, 1819 West Polk St., M/C 797, Chicago, IL 60612. Fax 312-413-0435; e-mail: psubbaia{at}uic.edu.

Background: Isoprostane F2{alpha} (iPF2{alpha}-III) concentration in plasma and urine is widely accepted as a measure of oxidative stress. Gas chromatography–mass spectrometry (GC/MS) methods for measuring iPF2{alpha}-III involve several steps of sample preparation and are labor-intensive, and ELISA methods, although easier to use, are less reliable. Therefore we developed a simple and sensitive method involving 1-step sample cleanup and HPLC/MS quantification.

Methods: Samples of plasma or urine were enriched with a deuterated (iPF2{alpha}-III-D4) standard, treated with KOH to liberate the bound isoprostanes, then loaded onto an immunoaffinity column, and the bound isoprostane was eluted with 95% ethanol. The concentrated sample was injected onto a C-18 HPLC column, and the isoprostane was eluted with a gradient of acetonitrile in water and analyzed by electrospray negative ionization, selectively monitoring the ions 353.2 (iPF2{alpha}-III) and 357.2 (iPF2{alpha}-III-D4). The amount of isoprostane in the sample was calculated from the ratio of the intensities of the 2 ions.

Results: The described method has a detection limit of 0.5 ng/L, with a linear dynamic range of 1–5000 ng/L. The intra- and interassay imprecisions were 4.68% and 3.88%, respectively. The values obtained correlated strongly with the GC/MS procedure (r = 0.80), but the absolute values were ~4– to 5-fold lower, because the present method measures specifically 1 isomer of isoprostane, whereas the GC/MS method measures 4 isomers together.

Conclusions: Because of its simplicity and lower limit of quantification, the present method provides a useful noninvasive tool for determining oxidative stress in patients.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.